$46.74 billion is the projected size of the global biotech supply chain market by 2034, up from $24.77 billion in 2026 and $23.50 billion in 2025, implying a 7.51% CAGR.
Demand for biologics, vaccines and advanced therapies is driving that growth because these products need validated cold storage, temperature-controlled transport, real-time monitoring and compliant distribution.
Cold-chain specialization is reshaping the market: services led in 2025, software/platforms are forecast to grow at a 10.72% CAGR, and cell and gene therapy logistics is set to expand fastest at 14.45%.
High costs for cryogenic infrastructure, ultra-low temperature equipment and trained quality teams remain a key brake, especially for smaller biotech firms and emerging-market suppliers.
North America stayed the largest region at $11.52 billion in 2025, while major players including Deutsche Post, UPS Healthcare, Cencora and FedEx are expanding through partnerships, acquisitions and technology investment.